News

 

 

Adherium Appoints New CEO to Drive Global Growth

9 June 2017:link here

Read more about Adherium Appoints New CEO to Drive Global Growth

Dr Michael S. Perry appointed Avita Medical CEO

US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive...

Read more about Dr Michael S. Perry appointed Avita Medical CEO

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D.

Read more about AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

Avita Medical’s Board show confidence in company by taking payment in shares

Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge,...

Read more about Avita Medical’s Board show confidence in company by taking payment in shares

'The enemy of my enemy is my friend:' Couple turns to viruses to beat back superbug

By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET - Link here

Read more about 'The enemy of my enemy is my friend:' Couple turns to viruses to beat back superbug

Avita Medical Announces Positive Results from Pivotal Trial

Highlights

Read more about Avita Medical Announces Positive Results from Pivotal Trial

Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

15/05/2017 - link here

Read more about Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31,...

Read more about AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

Avita Medical initiates legal proceedings to cancel Renovacare patent

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here

Read more about Avita Medical initiates legal proceedings to cancel Renovacare patent

Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here

Read more about Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

1 2 3 4 5 ... 24